MX2022010520A - Macrociclos peptidicos contra acinetobacter baumannii. - Google Patents

Macrociclos peptidicos contra acinetobacter baumannii.

Info

Publication number
MX2022010520A
MX2022010520A MX2022010520A MX2022010520A MX2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A MX 2022010520 A MX2022010520 A MX 2022010520A
Authority
MX
Mexico
Prior art keywords
sup
acinetobacter baumannii
against acinetobacter
peptide macrocycles
macrocycles against
Prior art date
Application number
MX2022010520A
Other languages
English (en)
Inventor
Hans Hilpert
Hong Shen
taishan Hu
Sabine Kolczewski
Theodor Stoll
Konrad Bleicher
Bernhard Fasching
Alexander Alanine
Julien Beignet
Dwight Macdonald
Stephen Jackson
Carsten Kroll
Adrian Schaeublin
Helmut Thomas
Amal Wahhab
Claudia Zampaloni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022010520A publication Critical patent/MX2022010520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) (ver Fórmula) (I) en donde de X1 a X8 y de R1 a R8 son tal como se definen en el presente documento, así como sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere a la fabricación de compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos para el tratamiento de enfermedades e infecciones causadas por Acinetobacter baumannii.
MX2022010520A 2015-10-27 2018-04-26 Macrociclos peptidicos contra acinetobacter baumannii. MX2022010520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15191743 2015-10-27
CN2016100125 2016-09-26

Publications (1)

Publication Number Publication Date
MX2022010520A true MX2022010520A (es) 2022-09-19

Family

ID=57200005

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005236A MX2018005236A (es) 2015-10-27 2016-10-24 Macrociclos peptidicos contra acinetobacter baumannii.
MX2022010520A MX2022010520A (es) 2015-10-27 2018-04-26 Macrociclos peptidicos contra acinetobacter baumannii.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005236A MX2018005236A (es) 2015-10-27 2016-10-24 Macrociclos peptidicos contra acinetobacter baumannii.

Country Status (26)

Country Link
US (3) US10030047B2 (es)
EP (1) EP3368544B1 (es)
JP (2) JP7286317B2 (es)
KR (1) KR102701379B1 (es)
CN (1) CN108350028B (es)
AU (1) AU2016347456B2 (es)
CL (1) CL2018000978A1 (es)
CO (1) CO2017013708A2 (es)
CR (1) CR20180232A (es)
DK (1) DK3368544T3 (es)
ES (1) ES2811911T3 (es)
HR (1) HRP20201273T1 (es)
HU (1) HUE050053T2 (es)
IL (1) IL258060B (es)
MX (2) MX2018005236A (es)
MY (1) MY193014A (es)
PE (1) PE20180796A1 (es)
PH (1) PH12018500904A1 (es)
PL (1) PL3368544T3 (es)
PT (1) PT3368544T (es)
RS (1) RS60662B1 (es)
RU (1) RU2729609C2 (es)
SI (1) SI3368544T1 (es)
TW (1) TWI720042B (es)
UA (1) UA124303C2 (es)
WO (1) WO2017072062A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106576092B (zh) * 2014-08-13 2019-11-19 华为技术有限公司 Fbmc信号的发送方法、接收方法和发射机以及接收机
HUE050053T2 (hu) 2015-10-27 2020-11-30 Hoffmann La Roche Makrociklusos peptidvegyületek Acinetobacter baumannii ellen
AU2017381656B2 (en) 2016-12-21 2020-07-02 F. Hoffmann-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
WO2018114879A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
EP3388444A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) * 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
WO2020126956A1 (en) * 2018-12-17 2020-06-25 F. Hoffmann-La Roche Ag Imidazopyrazine derivatives as antibacterial agents
JP7715634B2 (ja) 2019-03-08 2025-07-30 エフ． ホフマン－ラ ロシュ アーゲー 新規イミダゾール－ピラゾール誘導体
JP7715715B2 (ja) 2020-01-22 2025-07-30 エフ． ホフマン－ラ ロシュ アーゲー 新規複素環式化合物
EP4143190A1 (en) 2020-04-29 2023-03-08 F. Hoffmann-La Roche AG Antibacterial 8-phenylamino-3-(pyrazol-4-yl)imidazo[1,2-a]pyrazine derivatives
WO2021244997A1 (en) 2020-06-01 2021-12-09 F. Hoffmann-La Roche Ag Novel imidazopyrazne derivatives
JP2023529578A (ja) 2020-06-08 2023-07-11 エフ． ホフマン－ラ ロシュ アーゲー 新規イミダゾ－ピラジン誘導体
WO2021249896A1 (en) 2020-06-09 2021-12-16 F. Hoffmann-La Roche Ag Novel imidazopyrazine derivatives
EP4204090A1 (en) 2020-08-31 2023-07-05 F. Hoffmann-La Roche AG Imidazole-pyrazole derivatives as antibacterials
WO2022049011A1 (en) 2020-09-01 2022-03-10 F. Hoffmann-La Roche Ag Imidazole-pyrazole derivatives with anti-bacterial properties
EP4211116B1 (en) 2020-09-07 2024-08-07 F. Hoffmann-La Roche AG Novel heterocyclic antibiotics
JP2024506021A (ja) 2021-02-07 2024-02-08 エフ． ホフマン－ラ ロシュ アーゲー 新規ヘテロアリール置換イミダゾール誘導体
JP2024525550A (ja) 2021-07-06 2024-07-12 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染症の処置のための第４級アンモニウムカチオン置換化合物
JP2024525793A (ja) 2021-07-15 2024-07-12 エフ． ホフマン－ラ ロシュ アーゲー イミダゾール誘導体及びその抗生物質としての使用
WO2023161316A1 (en) 2022-02-25 2023-08-31 F. Hoffmann-La Roche Ag Zwitterionic antibacterial compounds
AU2023322412A1 (en) * 2022-08-09 2024-11-21 F. Hoffmann-La Roche Ag Process for manufacturing an antibiotic macrocyclic peptide
CN119708122A (zh) * 2023-09-27 2025-03-28 武汉人福创新药物研发中心有限公司 抗鲍曼不动杆菌的环肽及其应用
CN120424159A (zh) * 2024-02-02 2025-08-05 武汉人福创新药物研发中心有限公司 抗鲍曼不动杆菌的含羧酸取代的环肽及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660832B1 (en) * 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
DE10234422A1 (de) 2002-07-29 2004-02-12 Bayer Ag Antibakterielle Ester-Makrozyklen
RU2311415C2 (ru) * 2002-08-23 2007-11-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
NZ538522A (en) 2002-08-23 2008-03-28 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
ATE457995T1 (de) 2003-06-18 2010-03-15 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
EP1498422A1 (de) 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
AU2004261329B2 (en) 2003-07-31 2011-10-27 Ocera Therapeutics, Inc. Spatially-defined macrocyclic compounds useful for drug discovery
WO2005012332A1 (en) 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
CA2540646A1 (en) 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibacterial amide macrocycles
EP1737884B1 (en) 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
DE102004025731A1 (de) * 2004-05-26 2005-12-15 Bayer Healthcare Ag Antibakterielle Amid-Makrozyklen III
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
MX2007008640A (es) 2005-01-17 2007-09-12 Jerini Ag Antagonistas del receptor de c5a.
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008095999A1 (en) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Pyrimidine substituted macrocyclic hcv inhibitors
US20090275519A1 (en) 2008-02-08 2009-11-05 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
US8338565B2 (en) 2008-08-20 2012-12-25 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
US20120270769A1 (en) 2009-10-23 2012-10-25 Marsault Eric Methods of using macrocyclic inhibitors of serine protease enzymes
EP2493910A1 (en) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
CN103282510A (zh) 2010-08-13 2013-09-04 爱勒让治疗公司 拟肽大环化合物
CN103889437A (zh) 2011-08-31 2014-06-25 纽约大学 硫醚、醚和烷基胺连接的氢键替代物肽模拟物
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN103387601B (zh) 2012-05-11 2017-01-11 南开大学 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
CA2892027A1 (en) 2012-11-21 2014-05-30 Rqx Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
WO2014110420A1 (en) 2013-01-10 2014-07-17 Noliva Therapeutics Llc Peptidomimetic compounds
JP2017523197A (ja) 2014-07-30 2017-08-17 エービーエーシー セラピューティクス，エス．エル． ２−ピリドン部分を含む選択的抗菌剤としてのアリールヒドラジド
HUE050053T2 (hu) 2015-10-27 2020-11-30 Hoffmann La Roche Makrociklusos peptidvegyületek Acinetobacter baumannii ellen
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Also Published As

Publication number Publication date
HRP20201273T1 (hr) 2020-11-13
CO2017013708A2 (es) 2018-03-20
DK3368544T3 (da) 2020-08-24
EP3368544B1 (en) 2020-06-17
CL2018000978A1 (es) 2018-08-24
ES2811911T3 (es) 2021-03-15
PL3368544T3 (pl) 2020-11-16
CN108350028B (zh) 2021-12-07
UA124303C2 (uk) 2021-08-25
KR102701379B1 (ko) 2024-09-02
EP3368544A1 (en) 2018-09-05
KR20180063138A (ko) 2018-06-11
AU2016347456B2 (en) 2018-12-13
WO2017072062A1 (en) 2017-05-04
SI3368544T1 (sl) 2020-10-30
US11098080B2 (en) 2021-08-24
MY193014A (en) 2022-09-22
RS60662B1 (sr) 2020-09-30
TW201718565A (zh) 2017-06-01
US20170233437A1 (en) 2017-08-17
US20220411468A1 (en) 2022-12-29
CA2992926A1 (en) 2017-05-04
IL258060B (en) 2021-05-31
NZ738307A (en) 2024-02-23
JP2022024009A (ja) 2022-02-08
PH12018500904A1 (en) 2018-11-05
HK1258443A1 (zh) 2019-11-15
PT3368544T (pt) 2020-08-20
RU2018113426A3 (es) 2020-01-31
AU2016347456A1 (en) 2018-01-18
HUE050053T2 (hu) 2020-11-30
JP7286317B2 (ja) 2023-06-05
CR20180232A (es) 2018-05-31
US20180362578A1 (en) 2018-12-20
IL258060A (en) 2018-05-31
MX2018005236A (es) 2018-08-15
JP2018535960A (ja) 2018-12-06
US12012466B2 (en) 2024-06-18
RU2018113426A (ru) 2019-11-28
CN108350028A (zh) 2018-07-31
RU2729609C2 (ru) 2020-08-11
US10030047B2 (en) 2018-07-24
PE20180796A1 (es) 2018-05-09
TWI720042B (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12020551762A1 (en) Peptide macrocycles against acinetobacter baumannii
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
PH12016502081B1 (en) Compounds for treating spinal muscular atrophy
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
NZ708593A (en) Novel pyrazole derivative
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
EP4252848A3 (en) Oxysterols and methods of use thereof
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
PH12018500378A1 (en) Novel annelated phenoxyacetamides
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
EA201990656A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7